

## Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>

Islet preparation	1	2	3	4	5	6	7	8 <sup>a</sup>
<b>MANDATORY INFORMATION</b>								
Unique identifier	HPAP-020	HPAP-021	HPAP-023	HPAP-026	HPAP-028	HPAP-032	HPAP-034	HPAP-036
Donor age (years)	14	13	17	24	4	10	13	23
Donor sex (M/F)	M	F	F	M	M	F	M	F
Donor BMI (kg/m <sup>2</sup> )	13.2	21.4	21.35	20.8	17.3	16.3	18.6	16
Donor HbA <sub>1c</sub> or other measure of blood glucose control	NA	NA	8.9	4.9	9.8	9	5.2	5.2
Origin/source of islets <sup>b</sup>	nPOD	nPOD	nPOD	nPOD	nPOD	nPOD	UPENN	nPOD
Islet isolation centre	nPOD	nPOD	nPOD	nPOD	nPOD	nPOD	UPENN	nPOD
Donor history of diabetes? Please select yes/no from drop down list	Yes	Yes	Yes	No	Yes	Yes	No	No
<b>If Yes, complete the next two lines if this information is available</b>								
Diabetes duration (years)	5 days	7	7		3	3		
Glucose-lowering therapy at time of death <sup>c</sup>	Insulin	Insulin (Tresiba, Novolog)	Insulin (Humalog, Levemir)		Insulin (Lantis, Apidra)	Insulin (Humalog)		

*Continues on the next page*

RECOMMENDED INFORMATION								
Donor cause of death	DBD	DBD	DCD	DCD	DBD	DBD	DBD	DBD
Warm ischaemia time (h)								
Cold ischaemia time (h)								
Estimated purity (%)	35	30	60	90	40	30	70	90
Estimated viability (%)	92	93	95	92	88	88	95	92
Total culture time (h) <sup>d</sup>								
Glucose-stimulated insulin secretion or other functional measurement <sup>e</sup>								
Handpicked to purity? Please select yes/no from drop down list								
Additional notes								

<sup>a</sup>If you have used more than eight islet preparations, please complete additional forms as necessary

<sup>b</sup>For example, IIDP, ECIT, Alberta IsletCore

<sup>c</sup>Please specify the therapy/therapies

<sup>d</sup>Time of islet culture at the isolation centre, during shipment and at the receiving laboratory

<sup>e</sup>Please specify the test and the results

## Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>

Islet preparation	9	10	11	12	13	14	15	16
<b>MANDATORY INFORMATION</b>								
Unique identifier	HPAP-042	HPAP-047	HPAP-052	HPAP-064	HPAP-071	HPAP-080	HPAP-082	HPAP-084
Donor age (years)	1	8	27	24	12	22	25	12
Donor sex (M/F)	M	M	M	M	F	M	M	F
Donor BMI (kg/m <sup>2</sup> )	17.9	16.82	38.72	16.98	15.42	35.71	23.96	18.5
Donor HbA <sub>1c</sub> or other measure of blood glucose control	5.6	NA	5.2	13	9.8	5.4	5.6	13.3
Origin/source of islets <sup>b</sup>	nPOD	UPENN	UPENN	nPOD	nPOD	nPOD	nPOD	nPOD
Islet isolation centre	nPOD	UPENN	UPENN	nPOD	nPOD	nPOD	nPOD	nPOD
Donor history of diabetes? Please select yes/no from drop down list	No	No	No	Yes	Yes	No	No	Yes
<b>If Yes, complete the next two lines if this information is available</b>								
Diabetes duration (years)				Unknown, diagnosed at admission	3			Unknown
Glucose-lowering therapy at time of death <sup>c</sup>					Insulin glargine			Insulin

*Continues on the next page*

RECOMMENDED INFORMATION								
Donor cause of death	DCD	DBD	DBD	DBD	DBD	DBD	DCD	DBD
Warm ischaemia time (h)								
Cold ischaemia time (h)								
Estimated purity (%)	35	50	90	80	70	85	35	80
Estimated viability (%)	95	93	89	97	93	87	92	95
Total culture time (h) <sup>d</sup>								
Glucose-stimulated insulin secretion or other functional measurement <sup>e</sup>								
Handpicked to purity? Please select yes/no from drop down list								
Additional notes								

<sup>a</sup>If you have used more than eight islet preparations, please complete additional forms as necessary

<sup>b</sup>For example, IIDP, ECIT, Alberta IsletCore

<sup>c</sup>Please specify the therapy/therapies

<sup>d</sup>Time of islet culture at the isolation centre, during shipment and at the receiving laboratory

<sup>e</sup>Please specify the test and the results

## Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>

Islet preparation	17	18	19	20				
<b>MANDATORY INFORMATION</b>								
Unique identifier	HPAP-099	HPAP-104	HPAP-113	HPAP-123				
Donor age (years)	28	4	9	25				
Donor sex (M/F)	F	M	M	M				
Donor BMI (kg/m <sup>2</sup> )	24.7	20.63	15.92	21.35				
Donor HbA <sub>1c</sub> or other measure of blood glucose control	5	4.9	11.1	9.7				
Origin/source of islets <sup>b</sup>	UPENN	UPENN	nPOD	nPOD				
Islet isolation centre	UPENN	UPENN	nPOD	nPOD				
Donor history of diabetes? Please select yes/no from drop down list	No	No	Yes	Yes				
<b>If Yes, complete the next two lines if this information is available</b>								
Diabetes duration (years)			Unknown	3				
Glucose-lowering therapy at time of death <sup>c</sup>			Insulin	insulin glargine 100u/ml (13 units SQ) insulin regular,				

*Continues on the next page*

RECOMMENDED INFORMATION								
Donor cause of death	DBD	DBD	DBD	DBD				
Warm ischaemia time (h)								
Cold ischaemia time (h)								
Estimated purity (%)	85	90	80	90				
Estimated viability (%)	95	96	94	90				
Total culture time (h) <sup>d</sup>								
Glucose-stimulated insulin secretion or other functional measurement <sup>e</sup>								
Handpicked to purity? Please select yes/no from drop down list								
Additional notes								

<sup>a</sup>If you have used more than eight islet preparations, please complete additional forms as necessary

<sup>b</sup>For example, IIDP, ECIT, Alberta IsletCore

<sup>c</sup>Please specify the therapy/therapies

<sup>d</sup>Time of islet culture at the isolation centre, during shipment and at the receiving laboratory

<sup>e</sup>Please specify the test and the results